Articles NICE and Highly Specialised Technologies: three years on Leela Barham examines the process for the appraisal of Highly Specialised Technologies.
News NHS under fire for delaying access to rare disease cholester... Pharma concerned by fairness and transparency of NHS England's Prioritisation Framework
Articles Accelerating health technologies with NICE Office for Market... England's health watchdog launched its service to speed the delivery of new technologies in October 2015.
Articles The new Cancer Drugs Fund: sticking plaster 2.0 or a model f... A new, value-based Cancer Drugs Fund is set to be launched in England soon, but pharma companies fear it will be a step backwards for access to new cancer medicines.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
